Search - tctmd.com

Displaying 41 - 60 of 881

Sort: Relevancy | Date

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!)

Presenter: Andreas Baumbach, David Hildick-Smith, Ted Feldman

November 01, 2016

Presentation TCT 2016

TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials

Presenter: Zahid Amin, Jacqueline Saw, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

Editorial perspective: Interventional Treatment of Atrial Fibrillation: Current Strategy and Unmet Needs

Presenter: Vivek Y. Reddy

October 31, 2016

Presentation TCT 2016

Implantable Thermo-reactive Pulmonary Venous Stent for Atrial Fibrillation (Fulgur)

Presenter: Glenn Van Langenhove

October 31, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Presenter: Gary M. Ansel, Michael R. Jaff, Mehdi H. Shishehbor

October 30, 2016

Presentation TCT 2016

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

Presenter: Gary M. Ansel, Michael R. Jaff

October 30, 2016

Presentation TCT 2016

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Jean-Claude Laborde, Azfar G. Zaman

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Advertisement

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!)

TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials

Editorial perspective: Interventional Treatment of Atrial Fibrillation: Current Strategy and Unmet Needs

Implantable Thermo-reactive Pulmonary Venous Stent for Atrial Fibrillation (Fulgur)

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Atrial Fibrillation: Scope of the Problem

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content